Preclinical evaluation of 227Th-labeled and 177Lu- labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts

Nuclear Medicine Communications

Volumn 33, Issue 8, 2012, Pages 838-847

  Abbas, Nasir ^a   Bruland, Øyvind Sverre ^a,b   Brevik, Ellen Mengshoel ^c   Dahle, Jostein ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Algeta ASA   (Norway)

Author keywords

177Lu; 227Th; a radiation; b radiation; radioimmunotherapy; SKOV 3; trastuzumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LUTETIUM 177; RADIOISOTOPE; RITUXIMAB; TETRAXETAN; THORIUM 227; TRASTUZUMAB; UNCLASSIFIED DRUG; LUTETIUM; MONOCLONAL ANTIBODY; ORGANOMETALLIC COMPOUND; THORIUM 227 DOTA RITUXIMAB; THORIUM-227-DOTA-RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG SCREENING; FEMALE; GAMMA SPECTROMETRY; HISTOLOGY; ISOTOPE LABELING; LEUKOCYTE COUNT; LOW DRUG DOSE; MOUSE; NONHUMAN; OVARY CANCER; POST TREATMENT SURVIVAL; RADIATION DOSE; RADIOACTIVITY; THROMBOCYTE COUNT; WEIGHT REDUCTION; ANIMAL; COMPARATIVE STUDY; EXPERIMENTAL NEOPLASM; METABOLISM; OVARY TUMOR; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; LUTETIUM; MICE; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; PLATELET COUNT; RADIOISOTOPES; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84863490194     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328354df7c     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Agarwal R, Kaye SB. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3:502-516.
3. Ang C, Chan KK, Bryant A, Naik R, Dickinson HO. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011; 4:CD007697.
4. Karagiannis TC. Comparison of different classes of radionuclides for potential use in radioimmunotherapy. Hell J Nucl Med 2007; 10:82-88.
5. Seidl C, Zockler C, Beck R, Quintanilla-Martinez L, Bruchertseifer F, Senekowitsch-Schmidtke R. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Biimmunotherapy, but causes toxicity not observed with 213Bi. Eur J Nucl Med Mol Imaging 2011; 38:312-322.
6. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bonetargeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8:587-594.
7. Dahle J, Borrebaek J, Melhus KB, Bruland OS, Salberg G, Olsen DR, Larsen RH. Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy. Nucl Med Biol 2006; 33:271-279.
8. Larsen RH, Borrebaek J, Dahle J, Melhus KB, Krogh C, Valan MH, Bruland OS. Preparation of Th227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability. Cancer Biother Radiopharm 2007; 22:431-437.
9. Heyerdahl H, Krogh C, Borrebaek J, Larsen A, Dahle J. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-Trastuzumab. Int J Radiat Oncol Biol Phys 2011; 79:563-570.
10. Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: A historical perspective. Semin Oncol 2003; 30:10-21.
11. Keegan P. Supplement approval for Zevalin. Drugs@FDA 3-9-2009 Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction = Search.Label-ApprovalHistory#apphist [Accessed 4 May 2012].
12. Larsen RH, Akabani G, Welsh P, Zalutsky MR. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiat Res 1998; 149:155-162.
13. Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kolby L, Schmitt J, Forssel-Aronsson E. Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm 2003; 18:593-599.
14. Oei AL, Sweep FC, Thomas CM, Boerman OC, Massuger LF. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Int J Oncol 2008; 32:1145-1157.
15. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Jr. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994; 1:181-190.
16. Camilleri-Broet S, Hardy-Bessard AC, Le TA, Paraiso D, Levrel O, Leduc B, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: A multicenter study of the GINECO group. Ann Oncol 2004; 15:104-112.
17. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21:283-290.
18. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 2003; 63:5084-5090.
19. Palm S, Back T, Claesson I, Danielsson A, Elgqvist J, Frost S, et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys 2007; 69: 572-579.
20. Persson M, Gedda L, Lundqvist H, Tolmachev V, Nordgren H, Malmstrom PU, Carlsson J. [177Lu]pertuzumab: Experimental therapy of HER-2-expressing xenografts. Cancer Res 2007; 67:326-331.
21. Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, et al. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTAPESIN). Cancer Res 2011; 71:1009-1018.
22. Lindmo T, Bunn PA Jr. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol 1986; 121:678-691.
23. Institute for Transuranium Elements. Nuclide Explorer 2000. European Communities. Karlsruhe, Germany: Institute for Transuranium Elements; 2000.
24. Erwin WD, Groch MW, Macey DJ, DeNardo GL, DeNardo SJ, Shen S. A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol 1996; 23:525-532.
25. Miller WH, Hartmann-Siantar C, Fisher D, Descalle MA, Daly T, Lehmann J, et al. Evaluation of beta-Absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. Cancer Biother Radiopharm 2005; 20:436-449.
26. Moore DM. Hematology of the mouse (Mus musculus). In: Feldman BF, Zinkl JG, Jain NC, editors. Chalm's Veterinary Hematology. Philadelphia: Lippincott, Williams & Wilkins. 2000. pp. 1219-1224.
27. Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland OS, et al. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood 2007; 110:2049-2056.
28. Steffen AC, Gostring L, Tolmachev V, Palm S, Stenerlow B, Carlsson J. Differences in radiosensitivity between three HER2 overexpressing cell lines. Eur J Nucl Med Mol Imaging 2008; 35:1179-1191.
29. Kennel SJ, Mirzadeh S, Eckelman WC,Waldmann TA, Garmestani K, Yordanov AT, et al. Vascular-Targeted radioimmunotherapy with the alphaparticle emitter 211At. Radiat Res 2002; 157:633-641.
30. Sartor O, Bruland O. Stromal targeted therapies in prostate and renal cancer: New concepts and knowledge. Clin Genitourin Cancer 2011; 9:1-2.
31. Dahle J, Jonasdottir TJ, Heyerdahl H, Nesland JM, Borrebaek J, Hjelmerud AK, Larsen RH. Assessment of long-Term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Thrituximab. Eur J Nucl Med Mol Imaging 2010; 37:93-102.
32. Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003; 44:252-259.
33. Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW,Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11:4451-4459.